Comparing the current results to its competitors, Geovax Labs Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.73 %, recorded in the same quarter.
Geovax Labs Inc , slower than the average decrease reported by the company's competitors of -37.91 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -37.91 %
Geovax Labs Inc 's Comment on Competition and Industry Peers
GeoVax's product candidates compete with offerings from large pharmaceutical companies, specialty pharmaceutical and biotechnology firms, as well as academic and research institutions. The industry is marked by rapid technological changes, evolving standards, emerging competitors, and frequent new product introductions. Competitors possess existing products and technologies that rival GeoVax's pipeline candidates and may develop additional competing products and technologies. Some competing entities have greater financial resources, allowing for broader service and product lines and increased investments in research and development.
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Sources:
Geovax Labs Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Geovax Labs Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
